69C.F Tvardi Therapeutics Inc.

Healthcare Biotechnology Frankfurt Exchange
1.11 EUR
Close of Nov 11, 2026
0.5650 4.04
Market cap
EUR 14.8M
P/E
-
P/B
1.63x
ROE
-316.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 69C.F undervalued?

Graham number

The Graham number of Tvardi Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Tvardi Therapeutics Inc. fundamental analysis

No fundamental analysis for Tvardi Therapeutics Inc. yet.

Tvardi Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Tvardi Therapeutics Inc.

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathi…

Full company profile